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Introduction 
Disseminated superficial actinic porokeratosis, one 
of the most common variants of porokeratosis, is a 
skin condition with a genetic component that can be 
provoked with chronic sun exposure [1]. In this 
report, we describe a patient with longstanding 
disseminated superficial actinic porokeratosis 
(DSAP) who developed Her2/Neu-positive invasive 
ductal carcinoma of the left breast and subsequently 
underwent treatment with durvalumab, olaparib 
and paclitaxel. Durvalumab is an anti-programmed 
cell death ligand 1 (PD-L1) antibody currently FDA-
approved for the treatment of advanced urothelial 
carcinoma; it is also used in other solid tumors as an 
adjuvant with platinum-containing chemotherapy. 
Olaparib is a poly ADP-ribose polymerase (PARP) 
inhibitor (an enzyme involved in DNA repair) for 
ovarian breast and prostate cancer. 
Although inflammation of pre-existing DSAP has 
been described previously in the literature, namely 
with temozolomide (an alkylating agent) and 
Abstract 
Disseminated superficial actinic porokeratosis (DSAP) 
is an uncommon skin condition that can be inherited 
or may occur sporadically with multiple red-brown, 
thin plaques in a photodistribution. The condition 
more often affects middle-aged women and is often 
recalcitrant to therapy. In rare literature reports, 
systemic medications can trigger exacerbation or 
promote inflammation in pre-existing lesions of 
DSAP. We present a novel case of chemotherapy-
associated DSAP inflammation in a 66-year-old 
woman after triple therapy with durvalumab (PD-L1 
inhibitor), olaparib (PARP inhibitor) and paclitaxel, 
showing similarities to primary lichen planus-like 
eruption from immune checkpoint inhibitors. 
Figure 1. Chemotherapy-induced inflammation of disseminated 
superficial actinic porokeratosis (DSAP): Exam revealed a 
numerous amount of scattered inflamed appearing reddish-
brown thin papules with collarettes of scale distributed on the 
chest, arms and legs occurring 1 week after initiation of 
chemotherapy. 
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palifermin (a keratinocyte growth factor), this 
unusual phenomenon has yet to be reported with 
PD-L1 inhibitors or taxols. Clinical documentation of 
pre-existing DSAP lesions is key to avoid confusion 
with lichen planus-like eruptions associated with 
immune checkpoint inhibitors. Medical practitioners 
should be aware of the possibility of DSAP lesion 
exacerbation after the initiation of chemotherapy to 
avoid confusion and to prevent unnecessary 
discontinuation of chemotherapy. 
 
Case Synopsis  
A 66-year-old woman with a 20-year history of DSAP, 
basal cell carcinoma and recently diagnosed 
Her2/Neu-positive invasive ductal carcinoma of the 
left breast was referred by her oncologist with 
“worsening rash.” In the past few decades, she had 
visited the dermatology clinic for DSAP lesional 
treatment with topical imiquimod, topical 5-
fluorouracil, and photodynamic therapy with 
variable improvement, although relapsed 
consistently after treatment cessation. 
One week after initiating treatment with 
durvalumab/olaparib/paclitaxel, the previously 
documented lesions of DSAP became inflamed and 
deeply erythematous (Figure 1). Interestingly, she 
denied pruritus or pain. Review of systems was 
negative for fevers, chills, joint pain, photosensitivity, 
blisters, or oral lesions. Physical examination 
revealed scattered red-brown, thin papules and 
plaques with thread-like scale at the perimeter, 
widely distributed on the chest, arms, and legs with 
sparing of the back, abdomen, head, palms, and 
soles (Figure 1). Punch biopsy from the right thigh 
showed variable acanthosis and keratinocyte 
dysmaturation with random bizarre nuclei in concert 
with dyskeratotic keratinocytes (Figure 2A). A subtle 
tier of parakeratosis was also apparent. There was 
initial concern for toxic erythema of chemotherapy 
or PD-1-induced lichenoid drug eruption purely 
based on histopathologic findings. Additional shave 
biopsies were taken at a follow-up appointment in-
between the patient’s chemotherapy cycles and 
showed classic coronoid lamellae on several sections 
without keratinocyte dysmaturation (Figure 2B). 
Three weeks after her first chemotherapy cycle, all 
 
 
Figure 2. H&E histopathology. Dysmaturation of keratinocytes is 
evident in the spinous layer and singly necrotic keratinocytes are 
present throughout the epidermis akin to a toxic erythema-like 
interface reaction, 100×. B) A cornoid lamellae is emanating from 
an infundibular ostium, 100×. 
 
Figure 3. Between chemotherapy cycles (given every 6 weeks), the 
patient’s skin lesions appeared less inflamed and resembled her 
baseline exam, showing light erythematous to pink thin papules 
with a distinctive peripheral keratotic ridge. 
A 
B 
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lesions resembled the patient’s baseline exam, 
showing light erythematous to pink thin papules 
with a distinctive peripheral keratotic ridge (Figure 
3). However, her DSAP lesions continued to flare 
after each subsequent cycle of chemotherapy. A 
diagnosis of chemotherapy-induced inflammation 
of DSAP was rendered based on prior history, 
documented distribution of lesions in the same areas 
as her prior DSAP, and compilation of 
histopathologic findings. The patient was treated 
with topical emollients and counseled on 
photoprotective measures. 
 
Case Discussion  
The pathogenesis of porokeratosis is believed to 
relate to clonal proliferation of atypical keratinocytes 
[2]. Onset of DSAP is common around middle 
adulthood and among the six variants of 
porokeratosis, it tends to be the most generalized 
variant. The lesions are regarded as precancerous 
with 7.5% to 10% transformation risk to squamous 
cell carcinoma or basal cell carcinoma [3, 4]. The skin 
manifestations commonly consist of pink-brown 
annular keratotic papules and plaques that usually 
occur on sun-exposed areas of the body, sparing the 
palms and soles [1]. Histologically, the coronoid 
lamella is the microscopic hallmark for diagnosis [2]. 
The current treatment for DSAP includes imiquimod,  
ingenol mebutate, cryosurgery, photodynamic 
therapy, and topical or systemic therapy with 
retinoids, although all these treatments have limited 
success [1]. 
Chemotherapy-induced inflammation of actinic 
keratoses has been reported with several 
medications, including paclitaxel, 5-fluorouracil, 
doxorubicin, dacarbazine, vincristine, carboplatin, 
panitumumab and capecitabine [1]. However, 
chemotherapy-induced inflammation of DSAP has 
been rarely reported (Table 1) in independent 
reports with temozolomide and palifermin [4, 5]. Of 
note, treatment with the adjuvant palifermin during 
chemotherapy in a patient with DSAP eventually led 
to sustained clinical improvement and/or regression 
of DSAP lesions [4]. There has been one report of new 
onset DSAP after initiation of methotrexate and 
certolizumab pegol for psoriatic arthritis; the lesions 
regressed after certolizumab was discontinued [6]. 
Lichenoid inflammation commonly occurs in lesions 
of DSAP. The keratinocyte dysmaturation observed 
in our case is unique, as prior reports have not 
described “toxic erythema of chemotherapy-like” 
reaction in concert with lichenoid interface reaction. 
We attribute the dysmaturation seen on 
histopathology to the effects of taxol, although the 
lymphocytic infiltrate could be stemming from taxol, 
PDL-1 inhibitor, or PARP inhibitor.
Table 1. Prior reports of chemotherapy-induced inflammation of disseminated superficial actinic porokeratosis (DSAP) or 
chemotherapy-induced DSAP. 
Medication  
Pre-
existing 
DSAP 
Disease being 
treated Distribution  Bx Age/Sex Follow-up Reference  
Palifermin  Yes  CNS lymphoma  
Forearms & 
lower legs No 68M 
Sustained 
improvement  [4] 
Temozolomide Yes  Glioblastoma  Forearms  
Yes-Coronoid 
lamella  47M NA [5] 
Certolizumab/ 
Methotrexate No  
Psoriasis and 
psoriatic 
arthritis  
Trunk & 
extremities  
Yes- Coronoid 
lamella 62F 
Resolved 6 
weeks after d/c 
certolizumab 
[6] 
Durvalumab/ 
Olapartib/ 
Pacletaxol 
Yes  BRCA 
Upper & lower 
extremities  
Yes- Coronoid 
lamella and 
lichenoid 
inflammation  
66F  Present case 
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On balance, we suspect the PDL-1 agent to be the 
most intriguing culprit, based on overlap with prior 
immune checkpoint inhibitor-associated lichenoid 
drug eruptions. In the current case, the lack of a clear-
cut coronoid lamella in the first sample (despite level 
sections) led to additional sampling because of 
overall concern for a lichenoid drug eruption. 
Conventional lichenoid drug eruption was excluded 
based on the fact that the patient’s subsequent 
biopsies displayed a coronoid lamella and all skin 
lesions only involved sites of prior DSAP 
involvement. The presence of lichenoid 
inflammation on histopathology could have been 
further misconstrued as eruptive DSAP with 
concomitant lichenoid drug eruption if the patient 
did not have prior clinical documentation of DSAP. 
Given that most oncologists are unfamiliar with 
DSAP, this could be a potential pitfall in managing 
cancer patients with sun-damaged skin who are 
being treated with immunotherapy. 
 
Conclusion 
A patient treated with durvalumab/olaparib/ 
paclitaxel experienced an exacerbation of her DSAP 
lesions. Histopathology showed lichenoid 
inflammation which could have been misinterpreted 
as a lichenoid drug eruption. Her pre-existing history 
of DSAP, distribution localized to previously involved 
sites of DSAP, and the presence of a coronoid lamella 
histopathologically helped to confirm the diagnosis. 
Medical practitioners should be aware of the 
possibility of DSAP lesion exacerbation after the 
initiation of chemotherapy with durvalumab/ 
olaparib/paclitaxel to prevent misdiagnosis of 
lichenoid drug eruption and the unnecessary 
discontinuation of the chemotherapeutic 
intervention.  
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